Laparoscopy: The Competitor Intuitive Concedes ToWide moat
Intuitive Surgical (ISRG) — moat facet
The rival that needs no capital, no training and no clearance — and that Intuitive's own filing admits it may not displace.
The rival that has taken the most volume from Intuitive over twenty-seven years is not a robot. It is conventional laparoscopy, and it appears first in the company's own competition disclosure: "We face competition in the forms of existing open surgery, conventional MIS (laparoscopy), drug therapies, radiation treatment, and other emerging diagnostic and interventional surgical approaches. Some of these procedures are widely accepted in the medical community and, in many cases, have a long history of use."1
Laparoscopy needs no capital equipment, no $1,825 of proprietary consumables per case2, no training pathway and no service contract. It is performed by surgeons who already know how. In categories where it works well, the incremental clinical benefit of a robot is small and the incremental cost is not.
Intuitive makes the concession twice, about the two procedures adding the most volume to its United States business. On cholecystectomy: "given the already very high level of laparoscopic techniques used in cholecystectomy procedures, it remains unclear to what extent robotic-assisted surgery using da Vinci may continue to be adopted." On appendectomy: "similar to cholecystectomy procedures, there is currently a high level of laparoscopic techniques used"3. On hernia repair it adds that "we expect a large portion of hernia repairs will continue to be performed via different modalities of surgery."
That is the honest boundary of this business. Where the alternative is open surgery, robotics wins decisively — which is why urology converted. Where the alternative is a good laparoscopic technique, the argument is about minutes of operating time, complication rates and total cost of care, and it is fought case by case.
It is also why hospital economics matter more than technology. A da Vinci case has to be worth its cost to an administrator who has a cheaper option on the shelf, and that calculation gets harder when the hospital is under financial pressure — which is precisely the environment Intuitive's risk factors describe4.
Grade this on United States general surgery growth, 18% in 20255. That is the rate at which robotic assistance is still taking cases from laparoscopy, and it is the number the Extended Use Program is designed to protect.
Intuitive's own filing says robotic surgery may not displace laparoscopy in procedures where laparoscopy is already good. That was true a decade ago and it is true now; what changed is that the growth is arriving in exactly those procedures.
Every robotic case in the U.S. is one that could have been done laparoscopically or open. This count growing faster than surgical volumes shows robotics still taking cases from laparoscopy.
Source: Intuitive Surgical Form 10-K, FY2025 ↗- Moat Explorer calcSome of these procedures are widely accepted in the medical community and, in many cases, have a long history of use." Laparoscopy needs no capital equipment, no $1,825 of proprietary consumables per case, no training pathway and no...Moat Explorer calculation - arithmetic on figures reported in Intuitive's Form 10-K and Form 10-Q: instruments and accessories of $6,018.9M over 3,153,000 da Vinci plus 144,100 Ion procedures ($1,825 a procedure), service revenue of $1,572.1M over the installed base (about $134,000 a system), variable lease revenue of $531M over 1,810 usage-based systems (about $293,000), procedures over the average installed base (about 300 a system), each revenue line as a share of the $10,064.7M total, and US general surgery as a share of US procedures — FY2025 · publ. September 2026 · source ↗
- Moat Explorer calcSome of these procedures are widely accepted in the medical community and, in many cases, have a long history of use." Laparoscopy needs no capital equipment, no $1,825 of proprietary consumables per case, no training pathway and no...Moat Explorer calculation - arithmetic on figures reported in Intuitive's Form 10-K and Form 10-Q: instruments and accessories of $6,018.9M over 3,153,000 da Vinci plus 144,100 Ion procedures ($1,825 a procedure), service revenue of $1,572.1M over the installed base (about $134,000 a system), variable lease revenue of $531M over 1,810 usage-based systems (about $293,000), procedures over the average installed base (about 300 a system), each revenue line as a share of the $10,064.7M total, and US general surgery as a share of US procedures — FY2025 · publ. September 2026 · source ↗
- ReportedOn cholecystectomy: "given the already very high level of laparoscopic techniques used in cholecystectomy procedures, it remains unclear to what extent robotic-assisted surgery using da Vinci may continue to be adopted." On appendectomy:...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedA da Vinci case has to be worth its cost to an administrator who has a cheaper option on the shelf, and that calculation gets harder when the hospital is under financial pressure — which is precisely the environment Intuitive's risk...Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1A Risk Factors (the 559-system Chinese quota and Intuitive's placements under it, provincial limits on what hospitals may charge for robotic surgery, hospital financial pressure, and the warning that it may not recuperate the cost of a leased system) — FY2025 · publ. February 3, 2026 · source ↗
- ReportedGrade this on United States general surgery growth, 18% in 2025.Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗